Grifols (NASDAQ:GRFS) Upgraded at StockNews.com

StockNews.com upgraded shares of Grifols (NASDAQ:GRFS) from a hold rating to a buy rating in a report published on Thursday morning.

Separately, Morgan Stanley assumed coverage on shares of Grifols in a report on Wednesday, February 12th. They issued an “overweight” rating on the stock.

Grifols Trading Down 1.1%

Shares of Grifols stock opened at $7.76 on Thursday. Grifols has a 12-month low of $5.79 and a 12-month high of $9.96. The company has a market cap of $5.34 billion, a price-to-earnings ratio of 6.63 and a beta of 0.44. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The company’s 50-day moving average price is $7.29 and its 200-day moving average price is $7.63.

Institutional Investors Weigh In On Grifols

A number of institutional investors and hedge funds have recently modified their holdings of the company. Capital World Investors lifted its holdings in shares of Grifols by 0.7% in the fourth quarter. Capital World Investors now owns 21,134,230 shares of the biotechnology company’s stock worth $157,239,000 after buying an additional 154,358 shares in the last quarter. Brandes Investment Partners LP raised its stake in Grifols by 3.0% in the fourth quarter. Brandes Investment Partners LP now owns 20,496,093 shares of the biotechnology company’s stock valued at $152,491,000 after purchasing an additional 592,096 shares in the last quarter. Black Creek Investment Management Inc. raised its stake in Grifols by 1.3% in the fourth quarter. Black Creek Investment Management Inc. now owns 11,251,960 shares of the biotechnology company’s stock valued at $83,715,000 after purchasing an additional 141,615 shares in the last quarter. Soleus Capital Management L.P. raised its stake in Grifols by 46.1% in the fourth quarter. Soleus Capital Management L.P. now owns 6,605,425 shares of the biotechnology company’s stock valued at $49,144,000 after purchasing an additional 2,083,722 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Grifols by 1.9% in the first quarter. Goldman Sachs Group Inc. now owns 4,212,032 shares of the biotechnology company’s stock valued at $29,948,000 after purchasing an additional 80,507 shares in the last quarter.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.